Fournier Laboratories Ireland Ltd.

Primary objective: To determine the pharmacokinetic profile of fenofibric acid after single and multiple doses of ABT-335 in healthy Chinese male and female subjects. Safety objective: To evaluate the safety and tolerability of ABT-335 45 mg and 135 mg capsule formulations after single and multiple doses in healthy Chinese male and female subjects.

To evaluate the pharmacokinetics, safety and tolerability of ABT-493/ABT-530 after repeated oral administration under non-fasting conditions in healthy Chinese adult subjects

The main purpose of this study is to evaluate the efficacy of fenofibric acid in reducing triglycerides (TG) and increasing high-density lipoprotein cholesterol (HDL-C) after treatment in all patients with mixed dyslipidemia and hypertriglyceridemia; to evaluate the efficacy of fenofibric acid combined with statins and statins alone in reducing TG and increasing HDL-C in patients with mixed dyslipidemia. To evaluate the efficacy of fenofibric acid in reducing TG and increasing HDL-C in patients with hypertriglyceridemia.